Remove topic manufacturing-combination-drugs
article thumbnail

Is topical roflumilast set to become a dermatological panacea?

Hospital Pharmacy Europe

Topical roflumilast is being increasingly trialled for a number of skin conditions but how effective is it, and will it take centre stage in the field of dermatology? PDE4 inhibitors have become a promising class of drugs with a potential role in a number of therapy areas such as pulmonary, dermatological and neurological diseases.

FDA 98
article thumbnail

Forge Biologics and Labcorp partner for gene therapies development

Pharmaceutical Technology

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. In April 2023, Forge Biologics received a qualified person (QP) declaration for the manufacture of AAV gene therapies at its facility in Columbus, Ohio, US.

102
102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Regulatory, Compliance and Quality Challenges, Learnings, and Future Opportunities

ISPE

These technologies are not just trends; they are pivotal tools that enhance manufacturing processes, proactively address quality concerns, and expedite the development of life-saving drugs. Advanced therapies within combination products represent a frontier where pharmaceutical innovation meets medical technology.

FDA 98
article thumbnail

Analytica 2024 in overview

European Pharmaceutical Review

International participation and trending topics With over 900 exhibitors, analytica 2024 promises an impressive lineup. The analytica conference addresses this topic with a session on the applications of AI algorithms in laboratory medicine. Top topics at the trade fair include digitalisation, Laboratory 4.0,

article thumbnail

The Next Horizon for Therapy Innovations

ISPE

Many of these requirements include adhering to global regulatory harmonization, improving supply chain robustness, minimizing drug shortages, reducing the complexity of managing product life cycles, and reducing the environmental impact of pharmaceutical processes. One area affected by these shifts is the combination products.

article thumbnail

Five Achievements You Need To Unlock To Become An Antibiotic Ninja

IDStewardship

These are discussed here… Achievement 1: Bugs & Drugs. You do not necessarily need to memorize the antimicrobial spectra pages of the Sanford Guide, but you do need to have a general idea of which drugs cover which bugs. Macrolides, fluoroquinolones, and tetracyclines are go-to drugs for atypical bacteria.

226
226
article thumbnail

Incannex engages QPS for CannQuit and ReneCann

Pharmaceutical Technology

QPS is preparing the pre-investigational new drug applications to be submitted to the US Food and Drug Administration (FDA) and the EU’s European Medicines Agency (EMA) for the CannQuit and ReneCann products. French company Eurofins Scientific is currently developing and manufacturing both products.